Results for tag: "Boceprevir"

Boceprevir is a direct-acting antiviral drug used to treat chronic hepatitis C virus (HCV) infection. It is a protease inhibitor, which works by blocking the protease enzyme that HCV needs to replicate. Boceprevir is used in combination with other antiviral medications, such as pegylated interferon and ribavirin, to treat HCV genotype 1 infection. It is not effective against other genotypes of HCV. Boceprevir was approved by the US Food and Drug Administration (FDA) in 2011 and is marketed by Merck & Co. under the brand name Victrelis. It is available in capsule form and is taken orally three times a day with food. Boceprevir is an important treatment option for HCV infection, as it has been shown to improve response rates and reduce the duration of treatment. It is also associated with fewer side effects than other HCV treatments. In the Boceprevir market, Merck & Co. is the main player. Other companies involved in the market include Gilead Sciences, AbbVie, Bristol-Myers Squibb, and Janssen Pharmaceuticals. Show Less Read more